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Abstract Reliable biomarkers that can be used for early
diagnosis and tracking disease progression are the corner-
stone of the development of disease-modifying treatments
for Parkinson’s disease (PD). The German Society of
Experimental and Clinical Neurotherapeutics (GESENT)
has convened a Working Group to review the current status
of proposed biomarkers of neurodegeneration according to
the following criteria and to develop a consensus statement
on biomarker candidates for evaluation of disease-modi-
fying therapeutics in PD. The criteria proposed are that the
biomarker should be linked to fundamental features of PD
neuropathology and mechanisms underlying neurodegen-
eration in PD, should be correlated to disease progression
assessed by clinical rating scales, should monitor the actual
disease status, should be pre-clinically validated, and
conﬁrmed by at least two independent studies conducted by
qualiﬁed investigators with the results published in peer-
reviewed journals. To date, available data have not yet
revealed one reliable biomarker to detect early neurode-
generation in PD and to detect and monitor effects of drug
candidates on the disease process, but some promising
biomarker candidates, such as antibodies against neuro-
melanin, pathological forms of a-synuclein, DJ-1, and
patterns of gene expression, metabolomic and protein
proﬁling exist. Almost all of the biomarker candidates were
not investigated in relation to effects of treatment, vali-
dated in experimental models of PD and conﬁrmed in
independent studies.
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Introduction and aims of the present review
A biomarker (or biological marker) is deﬁned as a char-
acteristic that can be objectively measured and evaluated as
an indicator of normal biological processes, pathogenic
processes or pharmacologic responses to a therapeutic
intervention (Biomarkers Deﬁnitions Working Group
2001). According to the type of information they provide,
biomarkers for central nervous system (CNS) diseases can
be classiﬁed as clinical, neuroimaging, biochemical,
genetic or proteomic biomarkers. Biomarkers serve a wide
range of purposes, including conﬁrmation of diagnosis,
epidemiological screening, predictive testing, monitoring
of disease progression after diagnosis, drug development
and response to treatment, and studies of brain–behaviour
relationship.
There is a growing need for biomarkers of Parkinson’s
disease (PD, synonyms: idiopathic Parkinson syndrome,
paralysis agitans) pathology to improve drug development
related to the disease (Eller and Williams 2009; Gerlach
et al. 2008; Halperin et al. 2009; Maetzler et al. 2009a;
Marek et al. 2008; Michell et al. 2004; Morgan et al. 2010).
Current therapeutic strategies for PD focus primarily on
reducing the severity of its symptoms using dopaminergic
medications. Although these strategies signiﬁcantly
improve motor symptoms and the quality of life for
patients suffering from this neurodegenerative disease,
treatment does not slow or halt the underlying pathologic
processes. The goal of ﬁnding such a therapy (i.e., a neu-
roprotective or disease-modifying therapy) or one that
could reverse pathologic damage (i.e., a neurorestorative
therapy) is a major drive for preclinical research in PD.
Despite 25 years of work dedicated to this goal, success
has remained elusive. Several promising candidates for a
disease-modifying therapy have failed in human studies,
although they showed neuroprotective effects in experi-
mental models of PD. Problems with establishing a dis-
ease-modifying therapy arise from the complexity of the
disease process as well as the limitations of clinical tools
available to monitor the progression of the disease and to
observe the effects of an intervention. Major issues of the
complexity of the disease, which become frequently evi-
dent in clinical studies are the long duration and slow
progressive course of the disease, the variability and het-
erogeneity of symptoms and signs, cyclic episodes in
severity of the symptoms during the day related to the time
of medication (wearing-off and on/off ﬂuctuations) and
polypharmacy. In addition, misdiagnosis, co-morbidity and
co-medication add to the heterogeneity of the patient
population.
Since a disease-modifying therapy is likely to be most
effective early in the course of disease, early diagnosis is
highly desirable before neurodegeneration becomes severe
and widespread. Thus, there is a great need for biomarkers
that can be used for early diagnosis and tracking disease
progression to monitor a disease-modifying therapy.
The German Society of Experimental and Clinical
Neurotherapeutics (GESENT) has convened a Working
Group to develop a position paper and, if possible, a con-
sensus statement on biomarker candidates of neurodegen-
eration in PD for evaluation of disease-modifying
therapeutics. In June 2010, the Working Group met to
deﬁne the criteria for evaluation biomarkers of neurode-
generation in PD, to review the current status of all pro-
posed biomarkers of neurodegeneration according to the
deﬁned criteria and to develop this consensus statement.
This paper is planned as a basis for further discussion to
ﬁnally reach the goal of a comprehensive evaluation of
biomarkers for progression in PD.
Criteria for the development of biomarkers
of neurodegeneration in PD for proof
of disease-modifying therapeutics
Driven in part by Alzheimer’s disease (AD) drug discovery
research, AD is at the forefront of biomarker development
for CNS diseases, and many current concepts about ideal
biomarkers for PD have come from AD research (Frank
et al. 2003; Hampel et al. 2004, 2010; Shaw et al. 2007;
The Ronald and Nancy Reagan Research Institute of the
Alzheimer’s Association and the National Institute on
Aging Working Group 1998). We propose the following
criteria for an ideal biomarker to be useful to assess neu-
rodegeneration in PD and to evaluate disease-modifying
therapeutics: The biomarker should be
• linked to fundamental features of PD neuropathology
and mechanisms underlying neurodegeneration in PD,
• correlated to disease progression assessed by clinical
rating scales,
• able to monitor the actual disease status,
• pre-clinically validated,
• conﬁrmed by at least two independent studies con-
ducted by qualiﬁed investigators with the results
published in peer-reviewed journals.
In addition, an ideal biomarker of neurodegeneration
should be inexpensive, non-invasive, simple to use, and
technically validated (e.g., reliable, sensitive to change).
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Symptoms associated with motor function
The most widely used scale currently available for the
clinical evaluation of motor dysfunction in PD is the
Uniﬁed Parkinson’s Disease Rating Scale III (UPDRS-III)
(Goetz et al. 2007). This scale is subjective, has suboptimal
sensitivity, and it is widely accepted that more objective
and shorter assessments are needed. A promising tool is the
timed motor test, and, in particular, the pegboard test
(Haaxma et al. 2008). At group level, a trial using ‘‘change
from baseline’’ as endpoint and applying these tests would
require only 57–75% of the patients needed with the UP-
DRS-III (Haaxma et al. 2008).
In addition, there is a relevant and growing body of
literature which reports about objective, quantitative and
mobile assessments of movement disturbances in PD using
technical devices, such as accelerometers and gyroscopes.
A deﬁnite advantage of such methods is the possibility to
focus on cardinal motor disturbances, i.e. bradykinesia,
rigidity, tremor and postural instability, but also on prob-
lems of sensorimotor integration which is also a key
symptom associated with PD. So far, studies carried out
have mainly focused on the usefulness of the parameters in
differentiating PD from controls, but not on correlation
aspects, e.g. with disease duration. In addition, most of
them have not been put into context to clinical scales and
are thus not validated with regard to measuring disease
progression. Nevertheless, as these methods are generally
easy to perform (e.g. in an ambulatory setting), cheap,
unobtrusive, focus on mechanisms underlying the neuro-
degeneration in PD (e.g. cardinal motor symptoms), and
based on a well-investigated pathophysiological back-
ground (many of the investigated symptoms have been—
directly of indirectly—validated in pre-clinical models in
an extensive way), they should be seriously considered
when deﬁning e.g. an assessment panel for future pro-
gression studies in PD.
Mobile quantitative assessment of bradykinesia
According to the deﬁnition of Berardelli et al. (2001),
‘‘bradykinesia’’ encompasses problems of slowness or
absence of movement (including increased gait variability
and freezing): Promising quantitative markers are sit-to-
stand and stand-to-sit procedures (Bloem et al. 1997;
Hausdorff 2008; Najaﬁ et al. 2002; Weiss et al. 2010),
anticipatory postural adjustment (i.e. the attempt to vol-
untarily initiate the ﬁrst step to begin walking) (Carpinella
et al. 2007; Mancini et al. 2009), gait variability (Plotnik
et al. 2007, 2009), and peak arm swing velocity (Zampieri
et al. 2010).
Mobile quantitative assessment of rigidity
Rigidity is deﬁned as an increase in muscle tone leading to
a resistance to passive movement throughout the range of
motion. Promising quantitative markers are turning pro-
cedures when walking or receiving rotational perturbations
(Carpenter et al. 2004; Carpinella et al. 2007; Huxham
et al. 2008; Visser et al. 2007; Zampieri et al. 2010) and
straight walking (pelvic oscillations) (Huxham et al. 2008).
Mobile quantitative assessment of tremor
Although tremor is an obvious sign of PD, and clinically
easily to diagnose, the quantiﬁcation of this symptom
remains a technical challenge. In a study with PD patients
using electromyography, tremor amplitude and burst
duration increased, whereas frequency decreased with
longer disease duration (Milanov 2002). The ﬁrst results
with acceptable accuracy in detecting the severity of rest-
ing tremor using tri-axial accelerometers have been pub-
lished (Mamorita et al. 2009; Rigas et al. 2009; Schlesinger
et al. 2009).
Mobile quantitative assessment of postural instability
Accurate assessment of postural instability in PD remains
difﬁcult with currently available clinical measurement
tools, but may be quantiﬁable with ambulatory devices
which focus on anterior–posterior and medial–lateral
angular velocity deviations, e.g. at the trunk (Adkin et al.
2005). In addition, prospective detection of frequency of
near-falls and falls may be a promising approach to detect
PD progression.
Mobile quantitative assessment of sensorimotor integration
deﬁcits
There is an increasing awareness of sensorimotor integra-
tion deﬁcits in PD patients, and it is highly probable that
this feature also declines with increasing disease duration.
Promising markers may be the switch from kinaesthetic-
dependent to vision-dependent balance control (De Nunzio
et al. 2007), and overestimation of (balance) limits (Kamanli
et al. 2008).
Biomarker candidates of cognition
and neuropsychiatric symptoms
Cognitive symptoms
There is an increasing awareness of the high prevalence of
cognitive dysfunction in the course of PD. Independent
studies found a higher incidence of dementia in PD patients
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et al. 2001; de Lau et al. 2004). There is compelling evi-
dence that dementia prevalence increases with disease
duration (Maetzler et al. 2009a). Deterioration of cognitive
decline was most often assessed with the MMSE and the
cognitive section of the Cambridge Examination for
Mental Disorders (CAMCOG), two assessment tools vali-
dated for AD (Aarsland et al. 2004; Athey and Walker
2006). As cognitive symptoms in PD clearly differ from
AD symptoms, it was more and more realised that AD-
related assessment tools have relevant ﬂaws in determining
cognitive dysfunction in PD, and effort has been put into
the development of sensitive and reliable PD-relevant
measurement tools. One of the most promising tools is the
‘‘Scales for outcomes in Parkinson’s disease-cognition
(SCOPA-COG)’’ having advantages as compared to the
MMSE, the most important having a greater discriminative
capacity (Serrano-Duenas et al. 2010); however, longitu-
dinal studies are not yet available.
Hallucinations and depression
Based on the retrospective pathologically conﬁrmed (Wil-
liams and Lees 2005) and prospective studies (Forsaa et al.
2008; Goetz et al. 2005) visual hallucinations are regularly
observed in PD patients in particular at later disease stages,
and frequency increases with longer disease duration.
Depression has been shown to occur with higher inci-
dence in PD as compared to the general population, but
incidence and severity of symptoms may not relevantly
change during disease course (Karlsen et al. 1999; Rojo
et al. 2003; Schrag et al. 2007).
Sleep disturbances
Among a number of sleep disturbances which are associated
with PD rapid eye movement (REM) sleep behaviour dis-
order (RBD) may be the most promising biomarker candi-
date for detecting disease progression. A prospective
longitudinal study investigating patients with questionnaire
and polysomnography found an increase of RBD-associated
features from baseline (6–11% after 3, 24% after 6, and 39
percent after 8 years) (Onofrj et al. 2002). This increase in
occurrence could be conﬁrmed in an evidence level II study
with mid- to late-stage PD patients using a semi-structured
interview and a sleep questionnaire (Gjerstad et al. 2007).
Biomarker candidates of autonomic and sensory
dysfunction
Based on a controlled prospective study of 3 years duration
(Mesec et al. 1999) and a cross-sectional study (Linden
et al. 1997) heart rate variability decreases, and orthostatic
dysfunction probably increases with longer disease dura-
tion. A reduction in sympathetic skin response with
increasing disease duration has been demonstrated in two
cross-sectional studies (Orimo et al. 1999; Schestatsky
et al. 2006). Prevalence and severity of urinary and gas-
trointestinal symptoms most probably also increase during
PD course (Wullner et al. 2007); however, it may be dif-
ﬁcult to quantify these changes adequately.
There is compelling evidence from prospective longi-
tudinal studies (Diederich et al. 2002; Katsarou et al. 1998)
that visuospatial and colour discrimination deteriorate with
longer PD duration. These symptoms may be inﬂuenced by
medication status (Onofrj et al. 2002). There is no evidence
that olfactory dysfunction progresses signiﬁcantly during
PD course (Maetzler et al. 2009a).
Myocardial [
123I]metaiodobenzylguanidine (MIBG)
scintigraphy and [
18F]ﬂuorodopamine positron emission
tomography (PET) are used to detect local sympathetic
nerve damage in the heart, which regularly occurs in PD,
but rarely in healthy older people and in other forms of
parkinsonism. However, it is unlikely that cardiac sympa-
thetic innervation decreases with PD duration in the clini-
cal phase (Orimo et al. 1999; Shibata et al. 2009; Suzuki
et al. 2007).
Biomarker candidates of brain imaging
Presynaptic imaging of dopaminergic neurons is part of
clinical diagnostics of PD and appears to be a useful pro-
gression marker (Table 1). Disadvantages of this approach
are that the subjects are exposed to radioactivity, that the
costs are relatively high, and that the method is only
available at specialised centres. The imaging of the dopa-
minergic system is possible by measuring aromatic amino
acid decarboxylase activity (e.g. with [
18F]-DOPA) or by
visualisation of synaptic membrane dopamine transporter
(e.g. [
123I]b-CIT, [
123I]FP-CIT, [
123I]IPT, [
18F]CFT). In
longitudinal studies of PD progression, PET and single
photon emission computed tomography (SPECT) studies
using these tracers have shown an annualised striatal rate of
reduction in tracer uptake of about 4–13% in PD patients
versus 0–2.5% change in healthy controls (Marek et al.
2008; Nurmi et al. 2001). This decline may rather be
exponentially (Hilker et al. 2005). With regard to using
these functional imaging techniques for measuring disease
progression, it needs to be considered that correlations of
changes in imaging and clinical ﬁndings are rather incon-
sistent, probably, because different aspects of the disease
are reﬂected (Marek et al. 2008).
[
18F]-2-F-Deoxyglucose-PET may have some potential
in detecting metabolic changes associated with motor
(Huang et al. 2007) and cognitive decline (Huang et al.
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123Table 1 Qualiﬁcation of some biomarker candidates for the use in clinical trials of disease-modifying therapeutics in Parkinson’s disease (PD)
Analyte/method Link to
neuropathology/
pathomechanisms
Track of disease
progression
Monitoring the
actual
disease status
Validation in
experimental
models of PD
Conﬁrmation
by others
Clinical biomarker candidates
Mobile quantitative
assessment of
bradykinesia
Yes (cardinal
symptom)
Not investigated No (Yes: models
for bradykinesia)
Yes
Mobile quantitative
assessment of rigidity
Yes (cardinal
symptom)
Not investigated No (Yes: models for
rigidity)
Yes
Mobile quantitative
assessment of tremor
Yes (cardinal
symptom)
Not investigated No (Yes: models for
tremor)
Yes
Mobile quantitative
assessment of postural
instability
Yes (cardinal
symptom)
Not investigated No (Yes: models for
postural
instability)
No
Mobile quantitative
assessment of
sensorimotor integration
deﬁcits
No Not investigated ? No No
Sleep disturbances ? Yes Not investigated Not investigated Yes
Reduction in sympathetic
skin response
No Yes Not investigated Not investigated Yes
Visuospatial and colour
discrimination
Yes Yes No Not investigated Yes
Olfactory dysfunction Yes No Not investigated Not investigated Yes
Cardiac sympathetic
innervation
Yes No Not investigated Not investigated Yes
Neuroimaging biomarker candidates
[
18F]-DOPA-PET Yes Yes No Yes Yes
b-CIT–SPECT Yes Yes No Yes Yes
Magnet resonance imaging
(T2 relaxation time)
Yes No Not investigated Yes Yes
Biochemical biomarker candidates
Antibody response against
neuromelanin
Yes Not affected by disease
severity assessed by Hoehn
and Yahr staging and the
UPDRS
Negative correlation with
disease duration
It appears to be,
but has to be
conﬁrmed in
larger samples
Not investigated No
a-Synuclein concentrations
in the CSF
Yes No association with the
severity of PD
It appears to be,
but has to be
conﬁrmed in
larger samples
Not investigated No, there are
inconsistent
results
obtained
Complex I and IV activity
in platelet mitochondria
Yes Negative correlation between
activity and disease duration
Not investigated Not investigated No
8-Hydroxydeoxyguanosine
concentrations in urine
and blood
Yes Stage-dependent increase in
one study
Surprisingly no
effect of L-
DOPA therapy
in one study
Not investigated Yes
DJ-1 concentrations in the
CSF
Yes No association to severity of
PD
It appears to be,
but has to be
conﬁrmed in
larger samples
Not investigated No, there are
inconsistent
results
obtained
Reduced glutathione (GSH)
in CSF
Yes No association to severity of
PD
It appears to be,
but has to be
conﬁrmed in
larger samples
Not investigated No
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1232007; Liepelt et al. 2009), but these preliminary data
should be conﬁrmed in prospective longitudinal studies.
There is only limited evidence that magnetic resonance
imaging is of added value in detecting disease progression
in PD: Two cross-sectional studies with advanced PD
patients showed a positive correlation between T2 relaxa-
tion time in the putamen and disease duration which indi-
cates a progressive loss of iron (Graham et al. 2000; Ryvlin
et al. 1995). However, a recent study in PD patients and
controls measuring quantitative magnetic resonance
parameters sensitive to complementary tissue characteris-
tics (i.e. volume atrophy, iron deposition and microstruc-
tural damage) in six subcortical structures including the SN
and the putamen showed no relation of the relaxation rates
such as R2* as an indirect measure of the iron level to
disease progression (Peran et al. 2010).
Genetic and biochemical biomarker candidates
Genetic markers
PD-associated DNA variants (including mutations and
polymorphisms) are by deﬁnition predictive markers and
are not suitable for measuring progression. However, gene
expression proﬁling may be a promising approach for
deﬁning valuable progression markers as human SN pars
compacta of PD patients showed down-regulation of 68,
and up-regulation of 69 genes, as compared to control SN
(Grunblatt et al. 2004). Based on the recent publications
particularly interesting targets are pyridoxal kinase and
pyruvate metabolism (Ahmed et al. 2009; Elstner et al.
2009).
A recent study (Grunblatt et al. 2010) examined the
proﬁling of 12 transcripts via quantitative RT-PCR in RNA
originating from peripheral blood samples that were chosen
based on the previous postmortem brain proﬁling (Grunblatt
et al. 2004). Multiple analyses resulted in four signiﬁcant
genes: proteasome (prosome, macropain) subunit-a type-2
(PSMA2), laminin, b-2 (laminin S) (LAMB2), aldehyde
dehydrogenase 1 family-member A1 (ALDH1A1), and
histone cluster-1 H3e (HIST1H3E) differentiating between
medicated PD subjects versus controls. Using the combi-
nation of these four gene proﬁles for PD diagnosis, a sen-
sitivity and speciﬁcity of more than 80% was achieved. In
AD subjects, no signiﬁcant results were observed. There-
fore, the authors concluded that this combination is speciﬁc
for PD.
A transcriptome-wide scan using RNA microarrays in
whole blood of patients with early-stage PD (Scherzer et al.
2007) identiﬁed a molecular multigene marker that is
associated with risk of PD in 66 samples of the training set
comprising healthy and disease controls. This was further
validated in 39 independent test samples. Insights into
disease-linked processes detectable in peripheral blood are
offered by 22 unique genes differentially expressed in
patients with PD versus healthy individuals (Scherzer et al.
2007). These include the co-chaperone ST13, which sta-
bilises heat-shock protein 70, a modiﬁer of a-synuclein
misfolding and toxicity. ST13 messenger RNA copies are
lower in patients with PD than in controls in two inde-
pendent populations.
Biochemical markers
A summary of the most thoroughly investigated biochem-
ical biomarker candidates that may be used in the diag-
nostics of PD was published previously (Fasano et al. 2008;
Halperin et al. 2009; Morgan et al. 2010; Nyhlen et al.
2010). Here we focus on biomarker candidates with a
particular reference to their potential for monitoring neu-
rodegeneration and disease-modifying therapeutics.
Table 1 continued
Analyte/method Link to
neuropathology/
pathomechanisms
Track of disease
progression
Monitoring the
actual
disease status
Validation in
experimental
models of PD
Conﬁrmation
by others
Osteopontin in CSF Yes Positive (weak) correlation
with disease duration
It appears to be,
but has to be
conﬁrmed in
larger samples
Yes No
Total homocysteine in
plasma
No Correlation with disease
duration and duration of
L-DOPA treatment
Probably not Not investigated No, there are
inconsistent
results
obtained
CSF cerebrospinal ﬂuid, L-DOPA L-3,4-dihydroxyphenylalanine, PET positron emission tomography, SPECT single photon emission computed
tomography
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level by a relative selective destruction of neuromelanin
(NM)-containing dopaminergic cells in the SN pars com-
pacta (Hirsch et al. 1988). When melaninised dopaminergic
neurons die, NM is released from the degenerating cell
body and removed from the brain by the cells of the
immune system (Beach et al. 2007; Depboylu et al. 2011;
Orr et al. 2005). It was hypothesised that the removal of
NM from the brain by immune cells might stimulate an
antibody response that could be measured in blood. Indeed,
a novel enzyme-linked immunosorbent assay (ELISA) to
measure levels of antibodies against NM in human blood
sera (NM-ELISA) demonstrated an increased antibody
response in the sera of PD patients when compared with
age-matched controls (Double et al. 2009). The immune
response was not affected by disease severity assessed by
Hoehn and Yahr staging and the UPDRS. However, there
was a negative correlation with disease duration.
a-Synuclein is the major component of Lewy bodies,
one of the pathological hallmarks of PD, and mutations and
multiplications of the a-synuclein-encoding gene, SNCA,
have been found to cause familial forms of PD. Aberrant
metabolism of the protein has been suggested as a possible
driving force in the degenerative process of PD in a manner
similar to Ab1–42 in AD. Cerebrospinal ﬂuid (CSF) Ab1–42
levels in PD tend to be lower with longer disease duration
and cognitive decline (Maetzler et al. 2009b; Mollenhauer
et al. 2006). A recent study demonstrated that the CSF
fractalkine (an inﬂammatory marker)/Ab1–42 ratio was
positively correlated with PD severity in cross-sectional
samples as well a with PD progression in longitudinal
samples (Shi et al. 2011).
Increased concentrations of soluble a-synuclein oligo-
mers in plasma appear to have good speciﬁcity (85%) for
detecting PD when compared with controls in some studies
(El-Agnaf et al. 2006). The most consisting ﬁnding is
decreased a-synuclein concentrations in the CSF from PD
when compared with controls (see for a review, Morgan
et al. 2010; Nyhlen et al. 2010), but there is still no con-
vincing evidence that these levels change over disease
course (Hong et al. 2010). There is increasing evidence that
a-synuclein can be used to distinguish PD and related
synucleinopathies (dementia with Lewy bodies and multi-
ple system atrophy) from other movement disorders and
dementia (Mollenhauer et al. 2011); however, discrimina-
tory power is limited. In addition, the current a-synuclein
assays are limited because they do no not attempt to dis-
criminate between normal and pathological (phosphory-
lated and/or aggregated) forms of this protein.
The major hypotheses believed to contribute to the
eventual demise of nigral dopamine producing cells
include protein aggregation, oxidative stress, mitochondrial
dysfunction, dysfunction of proteasomal pathways and
neuroinﬂammation (Alvarez-Erviti et al. 2010; Chu et al.
2009; Double et al. 2010; Gerlach et al. 2006; Hatano et al.
2009; Schiesling et al. 2008; Yang et al. 2009). Complex I
and IV mitochondrial activity has been shown to be lower
in PD patients than in controls, and at very early disease
stages a negative correlation between complex I and IV
activity in platelet mitochondria, and disease duration has
been demonstrated (Benecke et al. 1993).
Markers of oxidative stress showed that in the blood of
PD patients there is either an increased production of free
radicals, reactive oxygen and nitrogen species or a dis-
turbed defence mechanisms against oxidative damage
(Gerlach et al. 2008; Morgan et al. 2010; Younes-Mheni
et al. 2007). However, these markers are not speciﬁc for PD
because similar results in other neurodegenerative diseases,
including AD were found. In addition, a variety of condi-
tions alter oxidative stress in a given patient (for example
normal ageing, smoking, vigorous exercise, antioxidants,
food, drugs, cancer, and chemotherapy), and these may be
hard to control for. Interestingly, some markers of oxida-
tive stress appear to be useful for tracking disease pro-
gression in PD. For example, concentrations of
8-hydroxydeoxyguanosine, a product of oxidised DNA,
were shown to be stage-dependently increased in the urine
of PD patients (Sato et al. 2005). Surprisingly, this increase
was not inﬂuenced by L-DOPA (3,4-dihydroxyphenylala-
nine, levodopa) therapy. Multiple large epidemiological
studies have demonstrated a reduced risk of developing PD
with higher concentrations of uric acid (a potent antioxi-
dant and free radical scavenger in the blood) in serum
(Schlesinger and Schlesinger 2008), but recent evidence
also indicates a potential for slower progression of PD with
higher uric acid levels (Schwarzschild et al. 2008). Clinical
use for uric acid as a biomarker is not supported by existing
knowledge, since the studies conclude that it is a risk
marker rather than a diagnostic marker. In addition, to date
there are no data available which make hope that uric acid
is a potential progression marker.
DJ-1 is a part of the cellular defence against oxidative
stress (Kahle et al. 2009), and mutations in its gene are
responsible for some forms of familial PD (Klein et al.
2009). A study has also found elevated DJ-1 levels in CSF
from patients with multiple sclerosis (Hirotani et al. 2008),
suggesting a link between secreted DJ-1, neuroinﬂamma-
tion and oxidative stress. Studies using CSF of PD patients
have demonstrated both increased (Waragai et al. 2006) and
decreased values compared with controls (Hong et al.
2010), thus warranting further investigations. In the study
by Hong et al. (2010), no association between DJ-1 and the
severity of PD was demonstrated. The results obtained from
studies using serum of PD patients are also inconsistent,
showing no change (Maita et al. 2008) or elevated con-
centrations compared with controls (Waragai et al. 2006).
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immune system. Using 2D-gel-electrophoresis, Goldknopf
et al. (2006) found differences in serum levels of nine
complement factors between PD and controls. Osteopontin
is a molecule with multiple functions, including modula-
tion of inﬂammatory response of microglia, and shows
much higher levels in CSF than in serum. Higher CSF and
serum levels are detectable in PD as compared to controls,
and there is some evidence that CSF osteopontin levels
increase with disease duration (Maetzler et al. 2007).
Several studies suggest that elevated plasma total
homocysteine, an endogenous product of methionine
metabolism, is a risk factor for cognitive impairment and
AD (Clarke et al. 1998; McCaddon et al. 2003). However,
other studies did not detect signiﬁcant associations with
AD or cognitive status (Miller et al. 2002). In agreement
with these studies, it was recently reported that plasma
total homocysteine concentrations did not differ across
AD, mild cognitive impairment, cerebral amyloid angio-
pathy, and non-demented control subjects, but were
increased in the PD group (Irizarry et al. 2005). The
elevated levels within the PD group were the result of
high concentrations of plasma total homocysteine in PD
patients treated with L-DOPA. Two cross-sectional studies
found also increased homocysteine plasma levels in PD
compared with controls, these levels correlated positively
with disease duration (Dos Santos et al. 2009; Hassin-
Baer et al. 2006). In one study, in addition, homocysteine
levels were associated with L-DOPA treatment duration,
but not with L-DOPA dose (Hassin-Baer et al. 2006). In
the other study (Dos Santos et al. 2009), L-DOPA treat-
ment did not signiﬁcantly correlate with plasma homo-
cysteine levels.
There are some interesting ﬁrst results which may
potentially reﬂect very early disease activity. Serum
insulin-like growth factor 1 (IGF-1) levels have been
shown to be higher in PD patients compared with controls,
with high levels in particular at early PD disease stages,
and a negative correlation between serum IGF-1 levels and
disease duration (Godau et al. 2010). In addition, using
rapidly processed CSF samples, we recently found lowered
levels of reduced glutathione in the CSF of Lewy body
disease patients as compared to controls (Maetzler et al.
2011)—which basically conﬁrms neuropathological ﬁnd-
ings in the brainstem of PD patients (Sian et al. 1994)—
and these levels were negatively associated with age but
not with disease-associated parameters. Thus, it is tempt-
ing to speculate that changes of the glutathione system,
similar to IGF-1, may be an early event in the disease
course.
Several recent studies have used hypothesis-unrelated,
explorative proteomic and metabolomic techniques to ﬁnd
novel biomarker candidates for PD in brain tissue and CSF
(see for a review Fasano et al. 2008; Morgan et al. 2010;
Nyhlen et al. 2010). Generally, these studies may be con-
sidered promising. However, these techniques require
considerable technical expertise and have not been well
tested for PD versus other neurodegenerative diseases and
the link to disease progression. In addition, the biomarker
candidates found in these studies need to be validated in a
greater and statistically signiﬁcant universe of individual
samples employing distinct methodologies, such as Wes-
tern blot, ELISA or single and multiple reaction monitoring
(Martins-de-Souza 2010).
A study using a multiplex quantitative proteomics
method for detecting biomarkers in the CSF of patients
with neurodegenerative diseases, including AD, dementia
with Lewy body and PD, suggests as potential candidates
for the clinical diagnosis of PD and monitoring disease
progression chromogranins, amyloid precursor protein-like
protein 1 and the prion protein (Abdi et al. 2006), but more
studies are needed to conﬁrm or refute the ﬁndings and to
assess the speciﬁcity of the protein proﬁles against other
neurodegenerative diseases (Zetterberg et al. 2008). Recent
research has identiﬁed an eight-protein CSF multi-analyte
proﬁle using proteomics that fully differentiate PD patients
from controls, with the proﬁle designation agreeing with an
expert clinical diagnosis of PD 95% of the time (Zhang
et al. 2008).
The idea that the whole metabolism, regulated by genes,
exogenous substances and proteins, might be affected in
diseased patients, and that these affected molecules could
together, form a distinct proﬁle, underlies metabolomics
(Kaddurah-Daouk and Krishnan 2005). This approach has
been tested in PD and some results appear promising, such
as the conﬁrmatory ﬁnding of reduced concentrations of
uric acid in plasma of idiopathic PD patients and PD
patients with LRRK2 mutations (Johansen et al. 2009).
However, both idiopathic and LRRK2 PD subjects involved
in this study were taking anti-parkinsonian medications,
and no samples from the un-medicated patients were
available. Therefore, it is possible that the observed sepa-
ration could be related to drug effects, which could involve
unknown drug metabolites and drug-induced changes in
metabolism.
Bogdanov et al. (2008) were able to accurately catego-
rise 25 controls and 66 un-medicated PD patients based
only on their metabolic proﬁles in blood, obtaining com-
plete separation between the two groups. Interestingly,
concentrations of 8-hydroxydeoxyguanosine, a marker of
oxidative DNA damage, were signiﬁcantly increased in PD
patients (conﬁrming results obtained in urine), but over-
lapped controls. In addition, concentrations of two other
markers of oxidative stress, uric acid and glutathione were
signiﬁcantly reduced and signiﬁcantly increased in PD,
respectively.
46 M. Gerlach et al.
123Review of some putative biomarkers for the use
in clinical trials of disease-modifying therapeutics
Table 1 summarises the qualiﬁcation of biomarker candi-
dates for the use in studies to proof disease-modifying
therapeutics by considering the criteria for the development
of biomarkers of neurodegeneration in PD as deﬁned
above. Qualiﬁcation is used to mean the establishment of
the credibility of a biomarker assay in its application to
questions relevant to drug treatment (Hampel et al. 2010).
Validation is usually applied to mean the determination of
the performance characteristics of an assay such as for
example sensitivity and speciﬁcity in measuring a speciﬁc
analyte. Qualiﬁcation requires speciﬁc patient populations
and a speciﬁc therapeutic intervention. For example, a
validated assay may be qualiﬁed as a PD biomarker to
detect and monitor effects of drug candidates on the disease
process by intervention in the a-synuclein aggregation, but
not in non-a-synuclein mechanisms. It could be said
therefore that the assay which was validated for quantiﬁ-
cation of a-synuclein ﬁbrillisation in the brain or CSF is
‘‘qualiﬁed for use’’ as a biomarker in a-synucleinopathies
such PD and Lewy body dementia for drugs that inhibit the
aggregation of a-synuclein. The ultimate use of a bio-
marker is a surrogate end point, which requires that a
biomarker has been qualiﬁed to substitute for a well-
established clinical endpoint such that the biomarker rea-
sonably predicts the clinical outcome and therefore can
serve as a surrogate (Hampel et al. 2010).
The ﬁrst criterion means that the biomarker is linked to
the neuropathology of PD and/or mirror fundamental
pathogenetic events in PD. The validity of a biomarker
with respect to a supposed pathogenetic mechanism will be
relevant for the evaluation of disease-modifying treat-
ments. Pathologically, PD is characterised by a preferential
loss of NM-containing dopamine neurons in the pars
compacta of the SN, with intracellular proteinaceous
inclusions named Lewy bodies in the SN and other brain
regions, and a reduction in striatal dopamine (Bernheimer
et al. 1973; Braak et al. 1995; Jellinger 1991). This ongoing
loss of nigral dopaminergic neurons mainly leads to clini-
cal diagnosis due to occurrence of motor symptoms such as
rigidity, tremor and bradykinesia, which results from a
reduction of about 70% of striatal dopamine (Bernheimer
et al. 1973; Riederer and Wuketich 1976).
To mirror a pathological feature it would be helpful to
know the cause of the disease. However, despite numerous
attempts, the cause of PD remains unclear. It is hypothe-
sised that the cause of neurodegeneration in PD is multi-
factorial in terms of both aetiology and pathogenesis.
Genetic factors are known to cause PD in small numbers of
patients with a familial form of the disorder. Mutations in
different genes (for example, SNCA-synuclein, LRRK2,
parkin, DJ1 and PINK1) have been identiﬁed, and PD
subtypes have been linked in addition to different chro-
mosomal loci (for example, Hatano et al. 2009; Schiesling
et al. 2008; Yang et al. 2009).These Mendelian forms of
PD are relatively rare. However, high-throughput geno-
typing and sequencing technologies have more recently
provided evidence that low-penetrance variants in some of
these and other genes may also contribute signiﬁcantly to
the aetiology of the common sporadic disease. Moreover,
rare variants in further genes, such as the glucocerebro-
sidase A gene associated with Gaucher’s disease, have
been found to be important risk factors in a subgroup of
patients (Gasser 2010). Therefore, an increasingly complex
interplay of different genes seems to contribute in distinct
ways to disease risk and progression. Hence, current
thinking favours the hypothesis that most sporadic cases
are caused by a complex interplay between different
genetic and environmental factors. This interplay may
result in alterations of biochemical cascades. Altered bio-
chemical pathways involved in the pathogenetic cascade of
events leading to cell dysfunction and neuronal cell death
in PD result among others in measurable mitochondrial
complex I deﬁciency, a disturbed iron metabolism, free
radicals, excitotoxicity, disturbed calcium homeostasis,
microglia activation and protein aggregation (Alvarez-
Erviti et al. 2010; Chu et al. 2009; Double et al. 2010;
Gerlach et al. 2006; Hatano et al. 2009; Schiesling et al.
2008; Yang et al. 2009).
The second criterion for the development of a biomarker
of neurodegeneration and to detect and monitor effects of
drug candidates on the disease process is that the biomarker
must track disease progression. We deﬁned a progression
marker as a disease-associated feature that changes in the
frequency of occurrence or severity, or both, over time.
The deﬁnitions used in our evaluation of progression of
features have been published previously (Maetzler et al.
2009a). For the qualiﬁcation of a biomarker as a surrogate
endpoint, there should be a link between a treatment-
induced change in the biomarker and the desired clinical
outcome measure, as well as a link between the treatment-
induced change in the biomarker and change of disease
process (Hampel et al. 2010).
Although imaging techniques measuring the presynaptic
nigrostriatal system with, for example [
18F]-DOPA or
[
123I]b-CIT, can readily distinguish subjects with early PD
from controls, and abnormalities can be observed even
before motor symptoms and signs are apparent, these
studies have been failed in monitoring both disease-modi-
fying (Ponsen et al. 2009) and neurorestorative therapies
(Freed et al. 2001; Whone et al. 2003). This was discussed
to be due, in part, to potential pharmacological modulation
or regulation of presynaptic proteins that may not relate to
the actual disease status. Therefore, we postulated as a third
Biomarker candidates of neurodegeneration in Parkinson’s disease 47
123criterion that the biomarker is monitoring the disease sta-
tus. This would require that the drug aimed to proof a
disease-modifying effect does not pharmacologically
inﬂuence the biomarker. To date, trials to proof disease-
modifying drugs have largely evaluated subjects in the
early clinical stages of the disease (generally untreated),
using clinical endpoints that involve either the change in a
classical clinical measure of the disease over time or pro-
gression to the point of reaching a disease milestone (for
example, need for a dopaminergic therapy). The greatest
concern in these studies has been the potential for the study
intervention to cause symptomatic beneﬁt that precludes
the determination of disease-modifying effects. Approa-
ches developed to overcome this problem, such as the
washout and delayed-start design, however, have either
failed to adequately overcome this problem or is not
without its own potential problems (Lang, 2010). There-
fore, clinical biomarkers that are changed by symptomatic
drug therapy cannot be considered sufﬁcient surrogate
biomarkers for the evaluation of disease-modifying
therapeutics.
The fourth criterion for the development of a biomarker
of neurodegeneration for proof of disease-modifying ther-
apeutics in PD is that the biomarker candidate is validated
in experimental models of PD. This means that in an in
vivo model of PD there should be a correlation between the
degree of neurodegeneration and the change of the bio-
marker candidate. In addition, based on the assumed
mechanism of action of a given compound, the proposed
mechanism underlying neurodegeneration should be modi-
ﬁed. This validation will be relevant for predicting the
response of PD patients to putative disease-modifying
therapies.
The ﬁfth criterion, validation of the biomarker in inde-
pendent studies is essential but also trivial. Only a pro-
gression marker that mirrors progression independent from
the investigator can be used as a biomarker for disease-
modifying therapeutics.
Conclusions and future perspectives
Reliable biomarkers that can be used for early diagnosis
and tracking disease progression are the cornerstone of the
development of disease-modifying treatments for PD. To
date, available data have not yet revealed one reliable
biomarker to detect early neurodegeneration in PD and to
detect and monitor effects of drug candidates on the disease
process, but some promising biomarker candidates, such as
antibodies against NM, pathological forms of a-synuclein,
DJ-1, and patterns of gene expression, metabolomic
and protein proﬁling exist (Table 1). Most of the reported
disease-associated changes are relatively small, with a
clinically problematic overlap between patients and con-
trols. Almost all of the biomarker candidates were not
investigated in relation to effects of treatment, validated in
experimental models of PD and conﬁrmed in independent
studies.
To solve some of the problems associated with the
development of biomarkers that can be used for early
diagnosis and tracking disease progression, the Parkinson’s
Progression Markers Initiative (PPMI) was founded
(http://www.ppmi-info.org). This public–private partnership
leaded by the Michael J. Fox Foundation aims to identify
clinical, imaging, and biological markers of disease pro-
gression. The emphasis will initially be on ﬂuid markers
including a-synuclein, DJ-1, amyloid b, and tau in CSF and
urate in blood. The initiative will enrol 400 newly diag-
nosed patients who are not yet on medication and who have
evidence of dopamine transporter loss on dopamine trans-
porter imaging with SPECT and 200 healthy age-matched
controls. As with the AD Neuroimaging Initiative (ADNI),
a crucial aspect of the PPMI is that all data and biological
specimens, stored in a central repository, will be available
for the research community. The PPMI will thus provide a
valuable resource to fuel further academic and industry-ini-
tiated studies and innovations, and promising biomarker
candidates identiﬁed through such efforts could be validated
and qualiﬁed against the large, prospective PPMI dataset.
However, to fulﬁl the promise of the PPMI for deliv-
ering objective biomarkers that can be used for early
diagnosis and tracking disease progression, specimen col-
lection, processing, and storage methods have to be
standardised. Further, quality-control mechanisms should
be in place to ensure data are acceptable before they are
made publicly available. Finally, well-deﬁned quantitative
biomarker outcomes that are consistent among many
research sites and laboratories should be established.
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